Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Functional analysis complements sequencing

Nov. 17, 2020

FDA complete response letter for sutimlimab cites third-party manufacturing issues

Nov. 16, 2020

Rallybio begins phase I/II study of RLYB-211 for fetal and neonatal alloimmune thrombocytopenia

Nov. 11, 2020

Medshine Discovery synthesizes new factor XIa inhibitors

Nov. 6, 2020

Adakveo approved in Europe to prevent VOCs in patients with sickle cell disease

Nov. 4, 2020

A novel inducer of fetal hemoglobin with improved PK and PD properties

Nov. 3, 2020

INSERM and collaborators describe hematopoietic stem cells including beta globin gene

Nov. 2, 2020

IND in effect for Fulcrum's phase I study of FTX-6058 for sickle cell disease

Oct. 5, 2020

Roche opens enrollment in phase III studies of crovalimab for PNH

Oct. 2, 2020

Discovery of new potent, selective and orally bioavailable inhibitors of factor XI

Oct. 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sanofi bets on Resalis’ oligonucleotide RES-010 for obesity
BioWorld
After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.